Current status of newborn screening worldwide: 2015

Seminars in Perinatology

Volumn 39, Issue 3, 2015, Pages 171-187

  Therrell, Bradford L ^a,b   Padilla, Carmencita David ^c,d   Loeber, J Gerard ^e   Kneisser, Issam ^f   Saadallah, Amal ^g   Borrajo, Gustavo J C ^h   Adams, John ⁱ  

^a National Newborn Screening and Genetics Resource Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e International Society for Neonatal Screening   (Netherlands)

^f SAINT JOSEPH UNIVERSITY   (Lebanon)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h Fundacion Bioquimica Argentina   (Argentina)

ⁱ Canadian Organization for Rare Disorders   (Canada)

Author keywords

Inborn errors of metabolism; International screening; Newborn screening; Rare disease screening

Indexed keywords

ADRENOLEUKODYSTROPHY; ARTICLE; ASIA; BANGLADESH; BLOOD ANALYSIS; CHINA; CONGENITAL HYPOTHYROIDISM; DRIED BLOOD SPOT TESTING; EDUCATION; EUROPE; GLOBOID CELL LEUKODYSTROPHY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLYCOGEN STORAGE DISEASE TYPE 2; HEARING IMPAIRMENT; HEART DISEASE; HUMAN; HUNTER SYNDROME; INBORN ERROR OF METABOLISM; INDIA; INDONESIA; INFANT MORTALITY; MAPLE SYRUP URINE DISEASE; MIDDLE EAST; MONGOLIA; MORBIDITY; NEW ZEALAND; NEWBORN SCREENING; NORTH AFRICA; NORTH AMERICA; PAKISTAN; PHILIPPINES; POINT OF CARE TESTING; PRIORITY JOURNAL; SCREENING TEST; SEVERE COMBINED IMMUNODEFICIENCY; SOUTH AND CENTRAL AMERICA; URINALYSIS; COOPERATION; GENETIC COUNSELING; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; NEWBORN; PARENTAL CONSENT; PILOT STUDY; PRACTICE GUIDELINE; PROCEDURES; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; TRENDS;

COOPERATIVE BEHAVIOR; GENETIC COUNSELING; GLOBAL HEALTH; GUIDELINES AS TOPIC; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PARENTAL CONSENT; PILOT PROJECTS; PUBLIC HEALTH;

EID: 84929668047     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2015.03.002     Document Type: Review

References (177)

1. Therrell B.L. Newborn dried bloodspot screening. Newborn Screening Systems-The Complete Perspective 2010, 133-156. Plural Publishing, Inc, San Diego. C.J. Driscoll, B. McPherson (Eds.).
2. Accessed 10.01.15. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/index.html.
3. Therrell B.L., Adams J. Newborn screening in North America. J Inherit Metab Dis 2007, 30:447-465.
4. Loeber J.G. Neonatal screening in Europe: the situation in 2004. J Inherit Metab Dis 2007, 30(4):430-438.
5. Bodamer O.A., Hoffman G.F., Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007, 30(4):439-444.
6. Padilla C.D., Therrell B.L. Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007, 30(4):490-506.
7. Borrajo G.J. Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis 2007, 30(4):466-481.
8. Saadallah A.A., Rashed M.S. Newborn screening: experiences in the Middle East and North Africa. J Inherit Metab Dis 2007, 30(4):482-489.
9. Lindner M., Abdoh G., Fang-Hoffman J., et al. Implementation of extended neonatal screening and a metabolic unit in the State of Qatar: developing and optimizing strategies in cooperation with the Neonatal Screening Center in Heidelberg. J Inherit Metab Dis 2007, 30(4):522-529.
10. White K.R., Forsman I., Eichwald J., Munoz K. The evolution of early hearing detection and intervention programs in the United States. Semin Perinatol 2010, 34(2):170-179.
11. Olney R.S., Ailes E.C., Sontag M.K. Detection of critical congenital heart defects: review of contributions from prenatal and newborn screening. Semin Perinatol 2015, 39(4). [this issue].
12. Hannon W.H., De Jesús V., Ballance L.O., et al. Blood collection on Filter Paper for Newborn Screening Programs-Approved Standard-Sixth Edition 2013, Clinical Laboratory Standards Institute, Wayne, PA, [CLSI document NBS01-A6].
13. Adeniran K.A., Limbe M. Review article on congenital hypothyroidism and newborn screening program in Africa; the present situation and the way forward. J Thyroid Disord Ther 2012, http://omicsgroup.org/journals/2167-7948/2167-7948-1-102.php?aid=4617%23.
14. Tshilolo L., Kafando E., Sawadogo M., et al. Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies. Public Health 2008, 122(9):933-941.
15. Mutesa L., Boemer F., Ngendahayo L., et al. Neonatal screening for sickle cell disease in Central Africa: a study of 1825 newborns with a new enzyme-linked immunosorbent assay test. J Med Screen 2007, 14(3):113-116.
16. Ohene-Frempong K., Oduro J., Tetteh H., Nkrumah F. Screening newborns for sickle cell disease in Ghana. Pediatrics 2008, 121:S120-S121.
17. Treadwell M.J., Anie K.A., Grant A.M., Ofori-Acquah S.F., Ohene-Frempong K.J. Using formative research to develop a counselor training program for newborn screening in Ghana. Genet Couns 2015, 24(2):267-277.
18. Adeniran K.A., Okolo A.A., Onyiriuka A.N. Thyroid profile of term appropriate for gestational age neonates in Nigeria: a forerunner to screening for congenital hypothyroidism. J Trop Pediatr 2010, 56(5):329-332.
19. Makani J., Soka D., Rwezaula S., et al. Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Trop Med Int Health 2015, 20(2):184-187.
20. McGann P.T., Ferris M.G., Ramamurthy U., et al. A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol 2013, 88(12):984-989.
21. Feleke Y., Enquoselassie F., Deneke F., et al. Neonatal congenital hypothyroidism screening in Addis Ababa, Ethiopia. East Afr Med J 2000, 77(7):377-381.
22. Tshilolo L., Aissi L.M., Lukusa D., et al. Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31,204 newborns. J Clin Pathol 2009, 62(1):35-38.
23. Lebea P.J., Pretorius P.J. Newborn screening for classic galactosemia and primary congenital hypothyroidism in the Nkangala district of the Mpumalanga province of South Africa. S Afr J Child Health 2008, 2(1):19-22.
24. Malan L, Reinecke CJ. Towards a newborn screening system for South Africa: the need for a systems approach. Proceedings of the 12th Annual CPTS Working Conference; 2006:62-78.
25. Morales A., Wierenga A., Cuthbert C., et al. Expanded newborn screening in Puerto Rico and the US Virgin Islands: education and barriers assessment. Genet Med 2009, 11(3):169-175.
26. Newborn Screening Task Force, American Academy of Pediatrics Serving the family from birth to the medical home. Newborn screening: a blueprint for the future. Pediatrics 2000, 106(suppl):S383-S427.
27. Public Law 110-204. Newborn screening saves lives Act of 2008. Accessed 26.12.14. https://www.govtrack.us/congress/bills/110/s1858/text.
28. Public Law 113-240. Newborn screening saves lives reauthorization Act of 2014. Accessed 26.12.14. https://www.govtrack.us/congress/bills/113/hr1281/text.
29. Accessed 26.12.14. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/index.html.
30. American College of Medical Genetics, Newborn Screening Expert Group Newborn screening: toward a uniform screening panel and system. Genet Med 2006, 8(suppl 1):1S-252S.
31. Kemper A.R., Green N.S., Calonge N., et al. Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. Genet Med 2014, 16(2):183-187.
32. Accessed 26.12.14. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/nominatecondition/workgroup.html.
33. Kwan A., Puck J. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol 2015, 39(4).
34. Verbsky J.W., Baker M.W., Grossman W.J., et al. Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol 2012, 32(1):82-88.
35. Kwan A., Church J.A., Cowan M.J., et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol 2013, 132(1):140-150.
36. Vogel B.H., Bonagura V., Weinberg G.A., et al. Newborn screening for SCID in New York State: experience from the first two years. J Clin Immunol 2014, 34(3):289-303.
37. Kwan A., Abraham R.S., Currier R., et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. J Am Med Assoc. 20 2014, 312(7):729-738.
38. Therrell B.L., Colleen W.U., Secretary of Health and Human Services Advisory Committee on Heritable Disorders in Newborns and Children, et al. Including the initial newborn screening bloodspot collection device serial number on birth certificates: basis and recommendations from the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC). Genet Med 2013, 15(3):229-233.
39. Duffner P.K., Caggana M., Orsini J.J., et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009, 40(4):245-252. [discussion 253-255].
40. De Jesús V.R., Zhou H., Vogt R.F. Dried blood spot quality control materials for newborn screening to detect lysosomal storage disorders. Clin Chem 2013, 59(8):1275-1276.
41. Matern D., Gavrilov D., Oglesbee D., et al. Newborn screening for lysosomal storage diseases. Semin Perinatol 2015, 39(4).
42. Hopkins P.V., Campbell C., Klug T., et al. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 2015, 166(1):172-177.
43. Hubbard W.C., Moser A.B., Liu A.C., et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009, 97(3):212-220.
44. Theda C., Gibbons K., Defor T.E., et al. Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible. Mol Genet Metab 2014, 111(1):55-57.
45. Turgeon C.T., Moser A.B., Mørkrid L., et al. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy. Mol Genet Metab 2015, 114(1):46-50.
46. Haynes C.A., De Jesús V.R. The stability of hexacosanoyl lysophosphatidylcholine in dried-blood spot quality control materials for X-linked adrenoleukodystrophy newborn screening. Clin Biochem 2015, 48(1-2):8-10.
47. Sorensen P.L., Gane L.W., Yarborough M., Hagerman R.J., Tassone F. Newborn screening and cascade testing for FMR1 mutations. Am J Med Genet A 2013, 161A(1):59-69.
48. Taylor J.L., Lee F.K., Yazdanpanah G.K., et al. Newborn bloodspot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin Chem 2015, 61(2):412-419.
49. Dobrowolski S.F., Pham H.T., Downes F.P., et al. Newborn screening for spinal muscular atrophy by calibrated short-amplicon melt profiling. Clin Chem 2012, 58(6):1033-1039.
50. Pyatt R.E., Mihal D.C., Prior T.W. Assessment of liquid microbead arrays for the screening of newborns for spinal muscular atrophy. Clin Chem 2007, 53(11):1879-1885.
51. Hahn S.H. Population screening for Wilson's disease. Ann N Y Acad Sci 2014, 1315:64-69.
52. Pasquali M., Schwarz E., Jensen M., et al. Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency. J Inherit Metab Dis 2014, 37(2):231-236.
53. Therrell B.L., Hannon W.H. Newborn dried blood spot screening: residual specimen storage issues. Pediatrics 2012, 129(2):365-366.
54. Caggana M., Jones E.A., Shahied S.I., et al. Newborn screening: from Guthrie to whole genome sequencing. Public Health Rep 2013, 128(suppl 2):S14-S19.
55. Rothwell E.W., Anderson R.A., Burbank M.J., et al. Concerns of newborn blood screening advisory committee members regarding storage and use of residual newborn screening blood spots. Am J Public Health 2011, 101(11):2111-2116.
56. Therrell B.L., Hannon W.H., Bailey D.B., et al. Committee Report: considerations and recommendations for national guidance regarding the retention and use of residual dried blood spot specimens after newborn screening. Genet Med 2011, 13(7):621-624.
57. Botkin J.R., Rothwell E., Anderson R., et al. Public attitudes regarding the use of residual newborn screening specimens for research. Pediatrics 2012, 129(2):231-238.
58. Bombard Y., Miller F.A., Hayeems R.Z., et al. Citizens' values regarding research with stored samples from newborn screening in Canada. Pediatrics 2012, 129(2):239-247.
59. Langbo C., Bach J., Kleyn M., Downes F.P. From newborn screening to population health research: implementation of the Michigan BioTrust for health. Public Health Rep 2013, 128(5):377-384.
60. Botkin J.R., Lewis M.H., Watson M.S., et al. Parental permission for pilot newborn screening research: guidelines from the NBSTRN. Pediatrics 2014, 133(2):e410-e417.
61. Accessed 09.01.15. http://www.ccmg-ccgm.org/index.php/publications/practice-guidelines-position-statements-and-reports.html.
62. Cross C. Ontario newborns now screened for SCID. CMAJ 2013, 185(13):E616.
63. Mercimek-Mahmutoglu S., Sinclair G., van Dooren S.J., et al. Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease. Mol Genet Metab 2012, 107(3):433-437.
64. Auray-Blais C., Cyr D., Drouin R. Quebec neonatal mass urinary screening programme: from micromolecules to macromolecules. J Inherit Metab Dis 2007, 30:515-521.
65. Auray-Blais C., Maranda B., Lavoie P. High-throughput tandem mass spectrometry multiplex analysis for newborn urinary screening of creatine synthesis and transport disorders, Triple H syndrome and OTC deficiency. Clin Chim Acta 2014, 25(436):249-255.
66. Khoo S.K., Dykema K., Vadlapatla N.M., et al. Acquiring genome-wide gene expression profiles in Guthrie card blood spots using microarrays. Pathol Int 2011, 61(1):1-6.
67. Bombard Y., Miller F.A., Hayeems R.Z., et al. Public views on participating in newborn screening using genome sequencing. Eur J Hum Genet 2014, 22(11):1248-1254.
68. Knoppers B.M., Sénécal K., Borry P., Avard D. Whole-genome sequencing in newborn screening programs. Sci Transl Med 2014, 6(229):229cm2.
69. Tahirovic H., Toromanovic A. Neonatal screening for congenital hypothyroidism in the Federation of Bosnia and Herzegovina: eight years' experience. Eur J Pediatr 2009, 168(5):629-631.
70. Tezel B., Dilli D., Bolat H., et al. The development and organization of newborn screening programs in Turkey. J Clin Lab Anal 2014, 28(1):63-69.
71. Loeber J.G., Burgard P., Cornel M.C., et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inher Metab Dis 2012, 35:603-611.
72. Burgard P., Rupp K., Lindner M., et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2-From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis 2012, 35:613-625.
73. Cornel M.C., Rigter T., Weinreich S.S., et al. Expert Opinion document Newborn screening in Europe. A framework to start the debate on neonatal screening policies in the EU. Eur J Hum Genet 2014, 22:12-17.
74. Groselj U., Tansek M.Z., Smon A., et al. Newborn screening in southeastern Europe. Mol Genet Metab 2014, 113(1-2):42-45.
75. Holmes D. Europe plays catch-up on neonatal screening as US skips ahead. Nat Med 2012, 18(11):1596.
76. Castellani C., Southern K.W., Brownlee K., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009, 8(3):153-173.
77. Sermet-Gaudelus S.J., Mayell K.W., et al. Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J Cyst Fibros 2010, 9:323-329.
78. Mayell S.J., Munck A., Craig J.V., et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009, 8(1):71-78.
79. Léger J., Olivieri A., Donaldson M., et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014, 99(2):363-384.
80. Fischer K.E., Rogowski W.H. Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe. Int J Environ Res Public Health 2014, 11(5):5403-5430.
81. Hom L.A., Martin G.R. U.S. international efforts on critical congenital heart disease screening: can we have a uniform recommendation for Europe?. Early Hum Dev 2014, 90(suppl 2):S11-S14.
82. Petrini C., Olivieri A., Corbetta C., et al. Common criteria among States for storage and use of dried blood spot specimens after newborn screening. Ann Ist Super Sanita 2012, 48(2):119-121.
83. Douglas C.M., van El C.G., Faulkner A., Cornel M.C. Governing biological material at the intersection of care and research: the use of dried blood spots for biobanking. Croat Med J 2012, 53(4):390-397.
84. Gauffin F., Nordgren A., Barbany G., Gustafsson B., Karlsson H. Quantitation of RNA decay in dried blood spots during 20 years of storage. Clin Chem Lab Med 2009, 47(12):1467-1469.
85. Hollegaard M.V., Grove J., Thorsen P., Norgaard-Pedersen B., Hougaard D.M. High-throughput genotyping on archived dried blood spot samples. Genet Test Mol Biomarkers 2009, 13:173-179.
86. Nicholls S.G., Southern K.W. Informed choice for newborn blood spot screening in the United Kingdom: a survey of parental perceptions. Pediatrics 2012, 130(6):e1527-e1533.
87. Allen J., McCarthy P., Dempsey E.M., Hourihane J.O. Guthrie cards in Republic of Ireland. Irish public would prefer legislation to protect Guthrie card archive rather than destroy it. Br Med J 2013, 347:f5232.
88. Mechtler T.P., Stary S., Metz T.F., et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012, 379(9813):335-341.
89. Paciotti S., Persichetti E., Pagliardini S., et al. First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Clin Chim Acta 2012, 413(23-24):1827-1831.
90. Rigter T., Weinreich S.S., van El C.G., et al. Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening. Mol Genet Metab 2012, 107(3):448-455.
91. Audrain M., Thomas C., Mirallie S., et al. Evaluation of the T-cell receptor excision circle assay performances for severe combined immunodeficiency neonatal screening on Guthrie cards in a French single centre study. Clin Immunol 2014, 150(2):137-139.
92. Adams S.P., Rashid S., Premachandra T., et al. Screening of neonatal UK dried blood spots using a duplex TREC screening assay. J Clin Immunol 2014, 34(3):323-330.
93. Olbrich P., de Felipe B., Delgado-Pecellin C., et al. A first pilot study on the neonatal screening of primary immunodeficiencies in Spain: TRECS and KRECS identify severe T- and B-cell lymphopenia. An Pediatr (Barc) 2014, 81(5):310-317. [article in Spanish].
94. la Marca G., Giocaliere E., Malvagia S., et al. The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry. J Pharm Biomed Anal 2014, 88:201-206.
95. Tauriscio D., Trama A., Stefanov R. Tackling rare diseases at European level: why do we need a harmonized framework?. Folia Med (Plovdiv) 2007, 49(1-2):59-67.
96. Shawky R.M. Newborn screening in the Middle East and North Africa-challenges and recommendations. Hamdan Med J 2012, 5(3):191-192.
97. Krotoski D., Namaste S., Raouf R.K., et al. Conference report: second conference of the Middle East and North Africa newborn screening initiative: partnerships for sustainable newborn screening infrastructure and research opportunities. Genet Med 2009, 11:663-668.
98. Solanki K.K. Training programmes for developing countries. J Inherit Metab Dis 2007, 30:596-599.
99. Fukushi M. An international training and support programme for the establishment of neonatal screening in developing countries. J Inherit Metab Dis 2007, 30(4):593-595.
100. Accessed 04.01.15. http://links.lww.com/GIM/A81.
101. Accessed 04.01.15. http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=139887.
102. Al-Alwani I., AlRowaeah A., Bawazeer M. Diagnosed congenital hypothyroidism with missing follow-up: is it time for a national registry?. Ann Saudi Med 2012, 32(6):652-655.
103. Shamshiri A.R., Yarahmadi S., Forouzanfar M.H., et al. Evaluation of current Guthrie TSH cut-off point in Iran congenital hypothyroidism screening program: a cost-effectiveness analysis. Arch Iran Med 2012, 15(3):136-141.
104. Golbahar J., Al-Khayyat H., Hassan B., et al. Neonatal screening for congenital hypothyroidism: a retrospective hospital based study from Bahrain. J Pediatr Endocrinol Metab 2010, 23(1-2):39-44.
105. Golbahar J., Al-Jishi E.A., Altayab D.D., et al. Selective newborn screening of inborn errors of amino acids, organic acids and fatty acids metabolism in the Kingdom of Bahrain. Mol Genet Metab 2013, 110(1-2):98-101.
106. Al Riyami S., Al Maney M., Joshi S.N., Bayoumi R. Detection of inborn errors of metabolism using tandem mass spectrometry among high-risk Omani patients. Oman Med J 2012, 27(6):482-485.
107. Al Obaidy H. Patterns of inborn errors of metabolism: a 12 year single-center hospital-based study in Libya. Qatar Med J 2013, 2013(2):57-65.
108. Abdel-Hamid M., Tisocki K., Sharaf L., Ramadan D. Development, validation and application of tandem mass spectrometry for screening of inborn metabolic disorders in Kuwaiti infants. Med Princ Pract 2007, 16(3):215-221.
109. El-Hazmi M.A., Al-Hazmi A.M., Warsy A.S. Sickle cell disease in Middle East Arab countries. Indian J Med Res 2011, 134(5):597-610.
110. Alkindi S., Al Zadjali S., Al Madhani A., et al. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates. Hemoglobin 2010, 34(2):135-144.
111. Hatam N., Shirvani S., Javanbakht M., Askarian M., Rastegar M. Cost-utility analysis of neonatal screening program, Shiraz University of Medical Sciences, Shiraz, Iran, 2010. Iran J Pediatr 2013, 23(5):493-500.
112. Sladkevicius E., Pollitt R.J., Mgadmi A., Guest J.F. Cost effectiveness of establishing a neonatal screening programme for phenylketonuria in Libya. Appl Health Econ Health Policy 2010, 8(6):407-420.
113. Khneisser I., Adib S.M., Loiselet J., Megarbane A. Cost-benefit analysis of G6PD screening in Lebanese newborn males. J Med Liban 2007, 55(3):129-132.
114. Al Hosani H., Salah M., Osman H.M., et al. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. East Mediterr Health J 2014, 20(1):17-23.
115. Al Arrayed S., Al Hajeri A. Newborn Screening Services in Bahrain between 1985 and 2010. Adv Hematol 2012, 2012:903219.
116. Khneisser I., Adib S.M., Megarbane A., Lukacs Z. International cooperation in the expansion of a newborn screening programme in Lebanon: a possible model for other programmes. J Inherit Metab Dis 2008, 31(suppl 2):S441-S446.
117. Lindner M., Abdoh G., Fang-Hoffmann J., et al. Implementation of extended neonatal screening and a metabolic unit in the State of Qatar: developing and optimizing strategies in cooperation with the Neonatal Screening Center in Heidelberg. J Inherit Metab Dis 2007, 30(4):522-529.
118. Somech R., Lev A., Simon A.J., et al. Newborn screening for severe T and B cell immunodeficiency in Israel: a pilot study. Isr Med Assoc J 2013, 15(8):404-409.
119. Babiker A.M.I., Al Jurayyan N.A., Mohamed S.H., Abdullah M.A. Overview of diagnosis, management and outcome of congenital hypothyroidism: a call for a national screening programme in Sudan. Sudanese J Pediatr 2012, 12(2):7-16.
120. Sarafoglou K., Bentler K., Gaviglio A., et al. High incidence of profound biotinidase deficiency detected in newborn screening blood spots in the Somalian population in Minnesota. J Inherit Metab Dis 2009, 32(suppl 1):S169-S173.
121. Gerner de Garcia B., Gaffney C., Chacon S., Gaffney M. Overview of newborn hearing screening activities in Latin America. Rev Panam Salud Publica 2011, 29(3):145-152.
122. Frómeta A., Reyes E.C., Castells E., et al. Quantitative ultramicrotest for newborn screening of galactosemia in Cuba. J Perinat Med 2011, 39(1):77-81.
123. González E.C., Frómeta A., del Río L., et al. Cuban neonatal screening of phenylketonuria using an ultramicro-fluorometric test. Clin Chim Acta 2009, 402(1-2):129-132.
124. González E.C., Marrero N., Pérez P.L., et al. An enzyme immunoassay for determining 17alpha-hydroxyprogesterone in dried blood spots on filter paper using an ultramicroanalytical system. Clin Chim Acta 2008, 394(1-2):63-66.
125. Campos D., Monaga M., González E.C., Herrera D. Identification of mucopolysaccharidosis I heterozygotes based on biochemical characteristics of L-iduronidase from dried blood spots. Clin Chim Acta 2014, 430:24-27.
126. Herrera D., Monaga M., Campos D., et al. Ultramicro-fluorometric assay for the diagnosis of Gaucher disease in dried blood spots on filter paper. J Neonatal Perinatal Med 2013, 6(1):61-67.
127. de Céspedes C., Saborío M., Trejos R., et al. Evolution and innovations of the National Neonatal and High Risk Screening Program in Costa Rica. Rev Biol Trop 2004, 52(3):451-466.
128. Queiruga G., Queijo C., Lemes A., Machado M., Garlo P., Salud Sistema Nacional de Pesquisa Neonatal en Uruguay. Mem Inst Investig Cienc 2011, 9(2):72-77.
129. Borrajo G. Panorama epidemiológico de la fenilcetonuria (PKU) en Latinoamérica. Acta Pediatr Mex 2012, 33(6):279-287.
130. Queijo C., Machado M., Franca F., et al. Pilot Programe for newborn screening using mass spectrometry in Uruguay. Rev Invest Clín 2009, 61(suppl 1):90.
131. Queijo C., Lemes A., Machado M., et al. Newborn screening of medium-chain acyl-CoA dehydrogenase deficiency in Uruguay. Acta Bioquím Clín Latinoam 2011, 45(1):87-93.
132. Accessed 30.12.14. http://www.unisert.org.br/Informativo_PNTN_8%C2%AA_ed.pdf.
133. Lopes M.E. The successful "Guthrie test" celebrates its 10th birthday in Brazil!. Cien Saude Colet 2011, 16(suppl 1):716-717.
134. Maciel L.M., Kimura E.T., Nogueira C.R., et al. Congenital hypothyroidism: recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq Bras Endocrinol Metabol 2013, 57(3):184-192.
135. Barone B., Lopes C.L., Tyszler L.S., et al. Evaluation of TSH cutoff value in blood-spot samples in neonatal screening for the diagnosis of congenital hypothyroidism in the Programa "Primeiros Passos"-IEDE/RJ. Arq Bras Endocrinol Metabol 2013, 57(1):57-61.
136. Norma Oficial Mexicana NOM-034-SSA2-2013. Para la prevención y control de los defectos al nacimiento. Accessed 30.12.14. http://www.dof.gob.mx/nota_detalle.php?codigo=5349816&fecha=24/06/2014.
137. González V., Santucci Z., Pattin J., et al. Programa de pesquisa neonatal de hipotiroidismo congénito de la Provincia de Buenos Aires: 1.377.455 niños evaluados en diez años de experiencia. Arch Argent Pediatr 2007, 105(5):390-397.
138. Accessed 30.12.14. http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/sivigila/Protocolos%20SIVIGILA/PRO%20Defectos%20Congenitos.pdf.
139. Ramírez C., Machado G., Lara M., Castellón E. Tamizaje neonatal para hipotiroidismo congénito en Nicaragua. Nicaragua Pediatr 2013, 1(2):6-10.
140. Padilla C.D., Therrell B.L. Screening newborns in the Asia-Pacific Region. Genomics and Health in the Developing World 2012, 764-781. Oxford University Press, Oxford. D. Kumar (Ed.).
141. Shi X.T., Cai J., Wang Y.Y., et al. Newborn screening for inborn errors of metabolism in mainland China: 30 years of experience. JIMD Rep 2012, 6:79-83.
142. Zhan J.Y., Qin Y.F., Zhao Z.Y. Neonatal screening for congenital hypothyroidism and phenylketonuria in China. World J Pediatr 2009, 5(2):136-139.
143. Lim J.S., Tan E.S., John C.M., et al. Inborn Error of Metabolism (IEM) screening in Singapore by electrospray ionization-tandem mass spectrometry (ESI/MS/MS): an 8 year journey from pilot to current program. Mol Genet Metab 2014, 113(1-2):53-61.
144. Padilla C. Enhancing case detection of selected inherited disorders through expanded newborn screening in the Philippines. Acta Med Philippina 2012, 46(4):24-29.
145. Hettiarachchi M., Amarasena S. Indicators of newborn screening for congenital hypothyroidism in Sri Lanka: program challenges and way forward. BMC Health Serv Res 2014, 12(14):385.
146. Leong Y.H., Gan C.Y., Tan M.A., Majid M.I. Present status and future concerns of expanded newborn screening in malaysia: sustainability, challenges and perspectives. Malays J Med Sci 2014, 21(2):63-67.
147. Yamaguchi S., Purevusren J., Kobayashi H., et al. Expanded newborn mass screening with MS/MS and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in Japan. J Jap Soc Mass Screen 2013, 23:270-276.
148. Morikawa S., Nakamura A., Fujikura K., et al. Results from 28 years of newborn screening for congenital adrenal hyperplasia in Sapporo. Clin Pediatr Endocrinol 2014, 23(2):35-43.
149. Heather N.L., Seneviratne S.N., Webster D., et al. Newborn screening for congenital adrenal hyperplasia in New Zealand 1994-2013. J Clin Endocrinol Metab 2015, 100(3):1002-1008.
150. Kitagawa T. Newborn screening for inborn errors of metabolism in Japan. A history of the development of newborn screening. Pediatr Endocrinol Rev 2012, 10(suppl 1):8-25.
151. Chien Y.H., Lee N.C., Chen C.A., et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr 2015, 166(4):985-991.
152. Yang C.F., Liu H.C., Hsu T.R., et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A 2014, 164A(1):54-61.
153. Chiang S.C., Hwu W.L., Lee N.C., Hsu L.W., Chien Y.H. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab 2012, 106(3):281-286.
154. Oda E., Tanaka T., Migita O., et al. Newborn screening for Pompe disease in Japan. Mol Genet Metab 2011, 104(4):560-565.
155. Han M., Jun S.H., Song S.H., et al. Use of tandem mass spectrometry for newborn screening of 6 lysosomal storage disorders in a Korean population. Korean J Lab Med 2011, 31(4):250-256.
156. Liao H.C., Chiang C.C., Niu D.M., et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan. Clin Chim Acta 2014, 431:80-86.
157. Hwu W.L., Chien Y.H., Lee N.C., Wang S.F., Chiang S.C., Hsu L.W. Application of mass spectrometry in newborn screening: about both small molecular diseases and lysosomal storage diseases. Top Curr Chem 2014, 336:177-196.
158. Lin S.P., Lin H.Y., Wang T.J., et al. A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 2013, 8:147.
159. Wang L.Y., Chen N.I., Chen P.W., et al. Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC Med Genet 2013, 10(14):24.
160. Inoue T., Hattori K., Ihara K., et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 2013, 58(8):548-552.
161. Morinishi Y., Imai K., Nakagawa N., et al. Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal Guthrie cards. J Pediatr 2009, 155(6):829-833.
162. Inaba Y., Schwartz C.E., Bui Q.M., et al. Early detection of fragile X syndrome: applications of a novel approach for improved quantitative methylation analysis in venous blood and newborn blood spots. Clin Chem 2014, 60(7):963-973.
163. Kim G.H., Yang J.Y., Park J.Y., et al. Estimation of Wilson's disease incidence and carrier frequency in the Korean population by screening ATP7B major mutations in newborn filter papers using the SYBR green intercalator method based on the amplification refractory mutation system. Genet Test 2008, 12(3):395-399.
164. Adayev T., LaFauci G., Dobkin C., et al. Fragile X protein in newborn dried blood spots. BMC Med Genet 2014, 15(1):119.
165. Charles T., Pitt J., Halliday J., Amor D.J. Implementation of written consent for newborn screening in Victoria, Australia. J Paediatr Child Health 2014, 50(5):399-404.
166. Maxwell S.J., O'Leary P. Newborn bloodspot screening: setting the Australian national policy agenda. Med J Aust 2014, 200(3):142-143.
167. Kapoor S., Gupta N., Kabra M. National newborn screening program still a hype or a hope now?. Indian Pediatr 2013, 50(7):639-643.
168. Verma I.C., Bijarnia-Mahay S., Jhingan G., Verma J. Newborn screening: need of the hour in India. Indian J Pediatr 2015, 82(1):61-70.
169. Therrell BL, Padilla CD Barriers to implementing sustainable national newborn screening in developing health systems. Int J Pediatr Adolesc Med. 2014;2(1):49-60. Accessed 20.04.15. http://www.sciencedirect.com/science/article/pii/S2352646714000179.
170. Padilla C.D., Therrell B.L. Consolidating newborn screening efforts in the Asia Pacific region: networking and shared education. J Community Genet 2012, 3(1):35-45.
171. CLSI Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Sixth Edition 2013, Clinical and Laboratory Standards, Institute, Wayne, PA, [CLSI document NBS01-A6].
172. CLSI Newborn Screening Follow-up; Approved Guideline-Second Edition 2013, Clinical and Laboratory Standards, Institute, Wayne, PA, [CLSI document NBS02-A2].
173. CLSI Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline 2009, Clinical and Laboratory Standards, Institute, Wayne, PA, [CLSI document NBS03-A].
174. CLSI Newborn Screening by Tandem Mass Spectrometry; Approved Guideline 2010, Clinical and Laboratory Standards, Institute, Wayne, PA, [CLSI document NBS04-A].
175. CLSI Newborn Screening for Cystic Fibrosis; Approved Guideline 2011, Clinical and Laboratory Standards, Institute, Wayne, PA, [CLSI document NBS05-A].
176. CLSI Newborn Blood Spot Screening for Severe Combined Immunodeficiency by Measurement of T-cell Receptor Excision Circles; Approved Guideline 2013, Clinical and Laboratory Standards, Institute, Wayne, PA, [CLSI document NBS06-A].
177. Accessed 14.01.15. http://www.isns-neoscreening.org/.